The human iPSC lines used in this study were derived from lymphocytes and lymphoblastoid cells collected from the COGA study participants obtained from the NIAAA/COGA Sharing Repository. These samples are deidentified. The selection criteria for these individuals were based on previously established PRS for AUD (12). Specifically, to investigate PRS for AUD, we selected eight individuals diagnosed with AUD according to the Diagnostic and Statistical Manual, fifth edition (84) with PRS greater than the 75th percentile and 10 individuals who had no history of AUD and exhibited PRS lower than the 25th percentile (table S1). Cryopreserved lymphocytes were thawed, and the erythroblastic cells expanded and infected with the Sendai virus, expressing reprogramming factors (CytoTune, Life Technologies). All reprogramming and assessment of pluripotency was performed by Sampled, formerly Infinity BiologiX LLC. Cultures of iPSC were maintained feeder free on Matrigel Matrix (Corning Life Sciences, catalog no. 354234) in mTeSR plus medium (STEMCELL Technologies, catalog #100-0276) and routinely passaged with Accutase (STEMCELL Technologies, catalog #07920). The experiments were done under the Rutgers Biosafety protocol #13-444.
